Clinical experience with the Sulcoflex add-on IOL in post-RLE dysphotopsia and ametropia
Session Details
Session Title: Pseudophakic IOLs: Monofocal/Accommodative
Session Date/Time: Tuesday 13/09/2016 | 16:30-18:00
Paper Time: 16:42
Venue: Hall C2
First Author: : H.Olesen DENMARK
Co Author(s): : T. Pedersen P. Furuskog
Abstract Details
Purpose:
To describe our results with a novel add-on IOL for sulcus implantation in pseudophakic eyes: Indications, methods of application and outcomes in terms of visual acuity, refractive precision and patient satisfaction.
Setting:
The Scandinavian branches of the Memira clinics (private refractive surgery)
Methods:
Review of 49 secondary lens implantations in 39 refractive patients treated in our clinics in Denmark, Norway and Sweden from September 2014 to February 2016. Analysis of patterns of application and effectiveness of the implant to relieve pseudophakic dysphotopsia and to correct residual ametropia.
Results:
Two main indications were found: 1) Dysphotopsia which was described in 20 eyes of 15 patients and 2) residual ametropia in pseudophakic eyes not elegible for laser vision correction. The latter group comprised 42 eyes, of which 12 also had significant dysphotopsia, so indications may overlap. For dysphotopsia the success rate was 100% with patients reporting complete absence or neglect of the phenomenon after Sulcoflex implantation. Implant powers ranged from -3,0 to +2,5 D sph. Nine of the implants were toric of which 1 needed reposition. More than 90 % of the eyes were within 0,25 diopter of the targeted refraction calculated on Rayner’s website. Four eyes (8%) subsequently needed laser vision correction.
Conclusions:
The Sulcoflex proved highly effective in relieving symptoms of dysphotopsia defined as a temporal crescent shaped visual sensation presumed to arise from a gap between the pupil and the IOL in the bag. The refractive accuracy is satisfactory with regard to sphere and cylinder. The toric variety, however, was found lacking in rotational stability.
Financial Disclosure:
NONE